Skip to main content
Premium Trial:

Request an Annual Quote

Private RNAi, miRNA Tech Firms Find VC Backers in 2008 Despite Financial Turmoil

Premium
Despite troubles on Wall Street hammering most publicly traded RNAi and microRNA companies (see related story, this issue) some private firms looking to commercialize drugs based on the technologies have managed to find interested venture-capital investors.
 
Since the beginning of 2008, privately held companies in the space collectively raised more than $78 million in venture and other private capital.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.